Home › Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
 

Keywords :   


Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease

2015-03-05 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with added study reduced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.04Migrants hit by high fees to send money home
30.04Physical checks to begin on EU-UK food and farm imports
29.04K-State researcher awarded $2.6 million to fight African swine fever
29.04Chairman Reinold Geiger Makes Offer To Take L\'Occitane Private
29.04FTC Fines Razer Over Misrepresented N95 Claims
29.04U by Kotex, Thinx and Walgreens Work to Fight Period Poverty
29.04US probes Ford hands-free driving tech after crashes
29.04Cattle markets are getting back on track
More »